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Disease Questionnaire (IBDQ)]. Over the years a standardized document was de-
veloped to help the authors to clarify the concepts and intent of each item of their
questionnaire(s). This document and examples will be presented. CONCLUSIONS:
This review demonstrates the lack of a formal, written concept lists for PRO ques-
tionnaires developed before the publication of the FDA guidance and the need to
develop standardized documents. Involvement of the developer(s) is crucial at this
step.
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NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS
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OBJECTIVES: Typically, mean costs and mean measures of effectiveness are used
in the estimation of the incremental cost effectiveness ratio (ICER). Cost and effec-
tiveness distributions, however, are often skewed. The goal of this work is to use a
nonparametric generalization of location to obtain a location region in the cost
effectiveness plane. The region accounts for uncertainty and all points in the re-
gion are appropriate estimates of the ICER that account for skewness in the mar-
ginal distributions.METHODS: First, analogous toMann-Whitney, all pairwise cost
and effectiveness treatment differences are computed. Using univariate methods,
an estimate of a location rectangle is obtained as the Cartesian product ofmarginal
location intervals, intervals that account for skewness. By considering the inter-
section of such rectangles over all orthogonal transformations, a closed convex
region is obtained. This method will then be applied to simulated bivariate cost
effectiveness data using both symmetric and skewed distributions. Kolmogorov-
Smirnov provides simultaneous confidence bands for each univariate rectangle.
Any point of this region is an estimate of the ICER; all such points satisfy basic
axioms of bivariate location. This approach will also be used to construct a gener-
alization of the cost effectiveness acceptability curve with uncertainty incorpo-
rated. A test for marginal skewness can precede the construction of the location
region. RESULTS: By comparing the location region with the usual bootstrap esti-
mates for the ICER, it was found that the location region approach produced con-
fidence intervals that were considerably larger for both skewed and symmetric
distributions of costs and effectiveness. CONCLUSIONS: This work provides esti-
mates of the ICER that appropriately accounting for skewness. In such cases, the
mean is not the best measure of location. In spite of the used of the nonparametric
bootstrap to obtain confidence intervals, skewness introduces an extra element of
variability that should be accounted for.
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OBJECTIVES: To show how the discrete modelling of continuously varying dose-
response relationships in cost-effective analysis (CEA) influences incremental
cost-effectiveness ratios (ICERs), cost-effectiveness acceptability curves (CEACs)
and the expected value of perfect information (EVPI). In particular, to show that
each of these metrics is contingent on the discrete comparisons chosen within a
CEA.METHODS: The cost-effectiveness of a hypothetical intervention with a con-
tinuous dose-response relationship is simulated. The cost-effectiveness of a small
number of possible dose levels is simulated first. The analysis is then repeated a
number of times, progressively increasing the number of possible doses and result-
ing combinations of costs and effects. For each run of the analysis ICERs are calcu-
lated for each dose level, a probabilistic sensitivity analysis is simulated, and
CEACs and the EVPI are plotted. RESULTS: As the number of potential cost and
effect combinations increases, the ICERs for each dose level increase, the CEACs fall
towards zero and the EVPI both rises and changes from having sharp inflection
points to being a smooth, downward-sloping curve. CONCLUSIONS: Many inter-
ventions demonstrate dose-response relationships, most of which are in principle
continuous, even if doses are typically varied discretely. The continuously increas-
ing intensity of interventionsmeans the number of possible alternatives is infinite.
The general conclusion from the analysis is that each of themetrics presented here
are contingent on the discrete comparisons chosenwithin the analysis. The signif-
icance of this finding for CEACs depends on their interpretation,which varies in the
literature. The significance for EVPI is that while it has previously been recognised
that excluding relevant comparators can reduce the EVPI, including all theoreti-
cally relevant alternatives may be impossible. Further work may be required to
understand this constraint on measuring the upper bound of the value of further
research.
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OBJECTIVES: To develop new schemes which can make the cost-effectiveness ac-
ceptability curve (CEAC) augmented to be more informative regarding the types of
acceptance and statistical inference.METHODS:Theoretical approaches have been
undertaken to address two questions: how the area under the curve (AUC) can be
zoned by the types of acceptance, and how the accepted dataset of incremental
cost-effectiveness ratios (ICERs), which are generated by computer runs, can be
statistically associated with a standard threshold of ICER. RESULTS: The AUC of a
typical sigmoid-shaped CEAC was divided into three zones, each of which repre-
sents the proportion, pi  ni / n(0), where ni is the number of plots on the cost-
effectiveness plain belonging to the quadrant i (i1:South-East, 2:North-East and
3:South-West), and n(0) is the total number of plots (i.e., n(0)n1n2n3) ac-
cepted for the threshold, 0, of ICER. A solution for the second question was “a new
CEAC of themean (MCEAC)”, which can be constructed by plotting a pair of m0 and
p0 instead of a pair of 0 and p0, where 0: the threshold of ICER for acceptance, p0:
the probability of acceptance for the threshold 0, and m0: the mean ICER of all the
plots accepted for the threshold 0. Also, statistical validity of the MCEAC was
inferred by the confidence interval of the mean m0 using t-test. Furthermore, the
series of confidence intervals defined for one threshold 0 corresponding to differ-
ent size of computer runs were summarized as a diagram for showing the progres-
sion of the confidence intervals, which looks similar to the forest plot in meta-
analysis. All those schemes were graphically illustrated based on examples.
CONCLUSIONS: Visualizing the component types of acceptance in the AUC, draw-
ing theMCEAC, and the progression diagramof confidence intervalswill provide us
with more useful information on cost-effectiveness decisions.
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OBJECTIVES:The objectivewas to summarize the impact of pharmacists’ interven-
tions on patient outcomes as reported in studies utilizing a randomized controlled
trial (RCT) design. METHODS: A comprehensive literature search was conducted
utilizing PubMed and International Pharmaceutical Abstracts for the years 1979-
2009. Studies were included if they evaluated pharmacist-provided interventions,
utilized RCT designs with control groups, andwere conducted in the United States.
Studies were summarized by 1) publication year; 2) study setting; 3) disease/health
condition; and 4) type of intervention provided and whether performed by a phar-
macist alone or a pharmacist with other health care professionals, 5) primary out-
come variables and 6) study findings. Patient outcome results were categorized as
‘positive’, if they found a statistically significant improvement in the patient out-
comes when compared to the control group, or ‘no difference’ if no significant
difference was found. RESULTS: Of the 552 citations reviewed, 100 studies met the
inclusion criteria. The numbers of pharmacists’ intervention studies conducted
using RCT designs increased from 1979 to 2009, with 64% conducted after 2000. The
majority of the studies were conducted in clinic setting (65%) followed by commu-
nity pharmacies (19%), hospitals (12%), home-care (2%), andmultiple settings (2%).
Chronic conditions were studied in 56% of the studies. Studies of interventions
delivered by pharmacists alone comprised 64%, while 36% involved pharmacists
workingwith other health care providers. Overall, ’positive’ patient outcomeswere
demonstrated in 73% of the studies. When interventions were delivered by phar-
macists working with other health care providers, however, 97.2% had positive
outcomes. CONCLUSIONS: ‘Positive’ patient outcomes were demonstrated in the
majority of the studies, supporting increased pharmacists’ roles in the health care
system to improve patient outcomes. When working alongside other health care
providers, the positive impact was most likely.
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OBJECTIVES: The word ‘hassle’ is commonly used in PRO measures including the
Morisky Medication Adherence Scale (MMAS-8). The translation of the word ‘has-
sle’ is used as an example of how creation of a concept elaboration and a full
translation and linguistic validation process can result in a translation that is con-
ceptually equivalent to the source text and to aid in the future translation of am-
biguouswords.METHODS:TheMMAS-8was translated into 29 languages using the
standard methodology of two forward translations, reconciliation, two back trans-
lations, back-translation review, developer review and proofreading. Examples of
translation issues of the word ‘hassled’ in the following statement were assessed:
Do you ever feel hassled about sticking to your anti-rejection treatment plan?
RESULTS: A ‘hassle’ is defined in the Oxford English Dictionary as an ‘irritating
inconvenience’. In the above question, this word encompasses several concepts –
bothered, troubled, disturbed – which were provided to translators in a concept
elaboration document. The translation process resulted in the following: The initial
French translation was back-translated as bothered/annoyed. Alternatives back-
translating as ‘preoccupied’ and ‘inconvenient’ were suggested but rejected. The
developer piloted the final suggestion, debordé (overwhelmed), with French-
speaking students, who agreed that this was the best translation in this context.
For other languages, ‘hassled’ was translated variously as: a nuisance, cumber-
some, difficult, bothersome, troubling, tiresome, irksome, burdensome and com-
plicated. These were queried with translator and the developer to confirm concep-
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